0001640455-18-000007.txt : 20180129 0001640455-18-000007.hdr.sgml : 20180129 20180129202632 ACCESSION NUMBER: 0001640455-18-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180126 FILED AS OF DATE: 20180129 DATE AS OF CHANGE: 20180129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Barbara Gayle CENTRAL INDEX KEY: 0001353128 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 18557290 MAIL ADDRESS: STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC. STREET 2: 18 DESBROSSES STREET CITY: NEW YORK STATE: NY ZIP: 10013 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_151727557738985.xml FORM 4 X0306 4 2018-01-26 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001353128 Duncan Barbara Gayle C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2018-01-26 4 M 0 4000 4.21 A 4000 D Common Stock 2018-01-26 4 S 0 4000 25 D 0 D Stock Option (Right to Buy) 4.21 2018-01-26 4 M 0 4000 4.21 D 2026-05-09 Common Stock 4000.0 46271 D The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trade. The Stock Option, representing the right to purchase a total of 50,271 shares of common stock, vests in 16 equal quarterly installments following May 10, 2016. /s/ Anna L. Barry, Attorney-in-Fact 2018-01-29